Eli Lilly expects sales growth to accelerate in second half of the year
Eli Lilly predicts accelerating growth in the second half of the year as production of its incretin-based drugs, including blockbuster drugs Mounjaro for type 2 diabetes and Zepbound for obesity, ramps up further.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly expects new drugs to drive 18% growth in 2024
For subscribers